Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
sEphB4-HSA with Chemotherapy/Cetuximab/RT in HNSCC
NCT04091867Phase 1Completed
- Sponsor
- University of Colorado Denver
- Start
- Jan 2020
- Primary completion
- May 2021
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of sephb4-hsa in head and neck squamous cell carcinoma (HNSCC), sponsored by University of Colorado Denver. Primary endpoint: Dose-Limiting Toxicity at 13 weeks. Started Jan 2020; status: completed.
02
Drugs
sephb4-hsa
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT04091867.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04091867.